// App-Quantinova.ai

262 : Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study

Researchers

Presenter

  • Y.H. Kim

Principal Investigators

  • S. Whittaker

  • S.M. Horwitz

  • M. Duvic

  • R. Dummer

  • J. Scarisbrick

  • P. Quaglino

  • P. Zinzani

  • P. Wolter

  • Y. Wang

  • M. Palanca-Wessels

  • E. Zagadailov

  • W.L. Trepicchio

  • H. Lin

  • M. Little

  • H. Prince

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

  • Univ Hosps Leuven, Leuven, Belgium

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Stanford, Stanford, CA.

  • U Hosp Zürich, Zürich, Switzerland

  • Takeda Oncology, Cambridge, MA.

  • U Turin, Turin, Italy

  • Univ Bologna, Bologna, Italy

  • MSKCC, New York, NY

  • Guy's and St. Thomas', London, United Kingdom

  • U Hosp Birmingham, Birmingham, United Kingdom

Locations

  • United States

  • Australia

  • Switzerland

  • Italy

  • United Kingdom

  • Belgium

Companies

  • Seattle Genetics, In

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Peripheral Nervous System

Disease

  • Cutaneous T-cell lymphoma

  • Peripheral neuropathy

  • Dyslipidemia

  • Mycosis fungoides

  • T-cell lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

  • Methotrexate

  • Bexarotene

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved